These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35550144)

  • 1. NOTCH-YAP1/TEAD-DNMT1 Axis Drives Hepatocyte Reprogramming Into Intrahepatic Cholangiocarcinoma.
    Hu S; Molina L; Tao J; Liu S; Hassan M; Singh S; Poddar M; Bell A; Sia D; Oertel M; Raeman R; Nejak-Bowen K; Singhi A; Luo J; Monga SP; Ko S
    Gastroenterology; 2022 Aug; 163(2):449-465. PubMed ID: 35550144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.
    Wang J; Dong M; Xu Z; Song X; Zhang S; Qiao Y; Che L; Gordan J; Hu K; Liu Y; Calvisi DF; Chen X
    Oncogene; 2018 Jun; 37(24):3229-3242. PubMed ID: 29545603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma.
    Ko S; Kim M; Molina L; Sirica AE; Monga SP
    Adv Cancer Res; 2022; 156():283-317. PubMed ID: 35961703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma.
    Zhang Y; Xu H; Cui G; Liang B; Chen X; Ko S; Affo S; Song X; Liao Y; Feng J; Wang P; Wang H; Xu M; Wang J; Pes GM; Ribback S; Zeng Y; Singhi A; Schwabe RF; Monga SP; Evert M; Tang L; Calvisi DF; Chen X
    Gastroenterology; 2022 Aug; 163(2):481-494. PubMed ID: 35489428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in mice.
    Ding N; Che L; Li XL; Liu Y; Jiang LJ; Fan B; Tao JY; Chen X; Ji JF
    World J Gastroenterol; 2016 Feb; 22(6):2071-80. PubMed ID: 26877611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice.
    Tao J; Calvisi DF; Ranganathan S; Cigliano A; Zhou L; Singh S; Jiang L; Fan B; Terracciano L; Armeanu-Ebinger S; Ribback S; Dombrowski F; Evert M; Chen X; Monga SPS
    Gastroenterology; 2014 Sep; 147(3):690-701. PubMed ID: 24837480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
    Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
    J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yap-Sox9 signaling determines hepatocyte plasticity and lineage-specific hepatocarcinogenesis.
    Liu Y; Zhuo S; Zhou Y; Ma L; Sun Z; Wu X; Wang XW; Gao B; Yang Y
    J Hepatol; 2022 Mar; 76(3):652-664. PubMed ID: 34793870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kupffer cells induce Notch-mediated hepatocyte conversion in a common mouse model of intrahepatic cholangiocarcinoma.
    Terada M; Horisawa K; Miura S; Takashima Y; Ohkawa Y; Sekiya S; Matsuda-Ito K; Suzuki A
    Sci Rep; 2016 Oct; 6():34691. PubMed ID: 27698452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular heterogeneity and transcriptomic profiles during intrahepatic cholangiocarcinoma initiation and progression.
    Wang T; Xu C; Zhang Z; Wu H; Li X; Zhang Y; Deng N; Dang N; Tang G; Yang X; Shi B; Li Z; Li L; Ye K
    Hepatology; 2022 Nov; 76(5):1302-1317. PubMed ID: 35340039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of YAP1 Signaling in Biliary Development, Repair, and Disease.
    Molina L; Nejak-Bowen K; Monga SP
    Semin Liver Dis; 2022 Feb; 42(1):17-33. PubMed ID: 35073587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrahepatic cholangiocarcinoma arising in chronic advanced liver disease and the cholangiocarcinomatous component of hepatocellular cholangiocarcinoma share common phenotypes and cholangiocarcinogenesis.
    Xu J; Sasaki M; Harada K; Sato Y; Ikeda H; Kim JH; Yu E; Nakanuma Y
    Histopathology; 2011 Dec; 59(6):1090-9. PubMed ID: 22175889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholangiocarcinomas can originate from hepatocytes in mice.
    Fan B; Malato Y; Calvisi DF; Naqvi S; Razumilava N; Ribback S; Gores GJ; Dombrowski F; Evert M; Chen X; Willenbring H
    J Clin Invest; 2012 Aug; 122(8):2911-5. PubMed ID: 22797301
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Matsumori T; Kodama Y; Takai A; Shiokawa M; Nishikawa Y; Matsumoto T; Takeda H; Marui S; Okada H; Hirano T; Kuwada T; Sogabe Y; Kakiuchi N; Tomono T; Mima A; Morita T; Ueda T; Tsuda M; Yamauchi Y; Kuriyama K; Sakuma Y; Ota Y; Maruno T; Uza N; Marusawa H; Kageyama R; Chiba T; Seno H
    Cancer Res; 2020 Dec; 80(23):5305-5316. PubMed ID: 33067264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sox9
    Tulasi DY; Castaneda DM; Wager K; Hogan CB; Alcedo KP; Raab JR; Gracz AD
    Cell Mol Gastroenterol Hepatol; 2021; 11(5):1437-1462. PubMed ID: 33497866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic interactions between hepatocyte nuclear factor-6 and Notch signaling regulate mouse intrahepatic bile duct development in vivo.
    Vanderpool C; Sparks EE; Huppert KA; Gannon M; Means AL; Huppert SS
    Hepatology; 2012 Jan; 55(1):233-43. PubMed ID: 21898486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF receptor-related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF-κB-inducing kinase-mediated hepatocyte transdifferentiation.
    Shiode Y; Kodama T; Shigeno S; Murai K; Tanaka S; Newberg JY; Kondo J; Kobayashi S; Yamada R; Hikita H; Sakamori R; Suemizu H; Tatsumi T; Eguchi H; Jenkins NA; Copeland NG; Takehara T
    Hepatology; 2023 Feb; 77(2):395-410. PubMed ID: 34995376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YTHDF1 promotes intrahepatic cholangiocarcinoma progression via regulating EGFR mRNA translation.
    Huang X; Zhu L; Wang L; Huang W; Tan L; Liu H; Huo J; Su T; Zhang M; Kuang M; Li X; Dai Z; Xu L
    J Gastroenterol Hepatol; 2022 Jun; 37(6):1156-1168. PubMed ID: 35233828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.
    Zhang S; Song X; Cao D; Xu Z; Fan B; Che L; Hu J; Chen B; Dong M; Pilo MG; Cigliano A; Evert K; Ribback S; Dombrowski F; Pascale RM; Cossu A; Vidili G; Porcu A; Simile MM; Pes GM; Giannelli G; Gordan J; Wei L; Evert M; Cong W; Calvisi DF; Chen X
    J Hepatol; 2017 Dec; 67(6):1194-1203. PubMed ID: 28733220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YAP Activation Drives Liver Regeneration after Cholestatic Damage Induced by
    Tharehalli U; Svinarenko M; Kraus JM; Kühlwein SD; Szekely R; Kiesle U; Scheffold A; Barth TFE; Kleger A; Schirmbeck R; Kestler HA; Seufferlein T; Oswald F; Katz SF; Lechel A
    Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30501048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.